BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tovorafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tovorafenib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05465174-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT05465174)
DESCRIPTION:Tovorafenib\, phase 2.\nStudy: Tovorafenib for Treatment of Cra
 niopharyngioma in Children and Young Adults\nEstimated primary completion:
  1 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovora
 fenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05465174
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381570-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20270321
DTEND;VALUE=DATE:20270322
SUMMARY:Tovorafenib: Phase 1 readout est. (NCT06381570)
DESCRIPTION:Tovorafenib\, phase 1\, Glioma.\nStudy: Pilot Study of Vinblast
 ine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF A
 ltered Low Grade Gliomas\nEstimated primary completion: 21 March 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tovorafenib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06381570
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775485-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT04775485)
DESCRIPTION:Tovorafenib\, phase 2\, Glioma.\nStudy: A Study to Evaluate Tov
 orafenib in Pediatric and Young Adult Participants With Relapsed or Progre
 ssive Low-Grade Glioma and Advance Solid Tumors\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tov
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04775485
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05566795-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tovorafenib: Phase 3 readout est. (NCT05566795)
DESCRIPTION:Tovorafenib\, phase 3\, Glioma.\nStudy: DAY101 vs. Standard of 
 Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requirin
 g First-Line Systemic Therapy (LOGGIC/FIREFLY-2)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovo
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05566795
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05828069-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT05828069)
DESCRIPTION:Tovorafenib\, phase 2.\nStudy: A Study With Tovorafenib (DAY101
 ) as a Treatment Option for Progressive\, Relapsed\, or Refractory Langerh
 ans Cell Histiocytosis\nEstimated primary completion: 30 September 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tovorafenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05828069
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206849-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT07206849)
DESCRIPTION:Tovorafenib\, phase 2\, Glioma.\nStudy: Study of Tovorafenib in
  High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)\nEstimated 
 primary completion: February 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tovorafenib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07206849
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965114-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Tovorafenib: Phase 1/2 readout est. (NCT06965114)
DESCRIPTION:Tovorafenib\, phase 1/2.\nStudy: Testing the Combination of Ant
 i-cancer Drugs\, Tovorafenib Plus Rituximab\, in Patients With Hairy Cell 
 Leukemia\nEstimated primary completion: 1 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tovorafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06965114
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441707-2192@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Tovorafenib: Phase 1 readout est. (NCT07441707)
DESCRIPTION:Tovorafenib\, phase 1\, Glioma.\nStudy: A Study to Assess a Med
 icine Called Tovorafenib in Japanese Children and Young Adults With Brain 
 Tumours\nEstimated primary completion: 31 July 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tovorafenib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07441707
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
